The Radiologic Spectrum of Neuroendocrine Tumors in Emergent Care

Overview

Journal Rev Endocr Metab Disord

Publisher Springer

Specialty Endocrinology

Date 2025 Jan 2

PMID 39745542

Authors

Asutosh Sahu

Michael Patlas

Ankush Jajodia

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine tumors (NETs) are a diverse group of neoplasms whose prevalence is increasing globally, primarily due to advancements in diagnostic techniques. NETs arise from cells of the diffuse endocrine system and can occur in various locations, with the gastrointestinal tract being the most common. Their diverse clinical presentations, which range from asymptomatic to severe hormone-induced syndromes, pose significant diagnostic challenges. In emergency care, prompt recognition and management of complications such as bowel obstruction, ischemic events, hormonal crises, and metastases are critical. This review discusses the radiologic spectrum of NETs in emergent care, emphasizing the role of imaging in timely diagnosis and intervention.

References

Zheng Z, Chen C, Jiang L, Zhou X, Dai X, Song Y . Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A population-based study. Cancer Med. 2019; 8(17):7288-7298. PMC: 6885880. DOI: 10.1002/cam4.2567. View

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens L . Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022; 33(1):115-154. DOI: 10.1007/s12022-022-09708-2. View

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

Lamberti G, La Salvia A . Neuroendocrine Tumors: Challenges and Future Perspectives. J Clin Med. 2022; 11(15). PMC: 9369270. DOI: 10.3390/jcm11154351. View

Rossi R, Massironi S . The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues. J Clin Med. 2022; 11(13). PMC: 9267138. DOI: 10.3390/jcm11133794. View

Das S, Dasari A . Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?. Curr Oncol Rep. 2021; 23(4):43. PMC: 8118193. DOI: 10.1007/s11912-021-01029-7. View

Vinik A, Chaya C . Clinical Presentation and Diagnosis of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2015; 30(1):21-48. DOI: 10.1016/j.hoc.2015.08.006. View

Rizen E, Phan A . Neuroendocrine Tumors: a Relevant Clinical Update. Curr Oncol Rep. 2022; 24(6):703-714. DOI: 10.1007/s11912-022-01217-z. View

Pirasteh A, Lovrec P, Bodei L . Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities. Rev Endocr Metab Disord. 2021; 22(3):539-552. DOI: 10.1007/s11154-021-09631-7. View

10.

Modica R, Benevento E, Liccardi A, Cannavale G, Minotta R, Di Iasi G . Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms. Minerva Endocrinol (Torino). 2024; 49(2):158-174. DOI: 10.23736/S2724-6507.23.04140-4. View

11.

Condron M, Pommier S, Pommier R . Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery. 2015; 159(1):358-65. DOI: 10.1016/j.surg.2015.05.036. View

12.

Caplin M, Pavel M, Cwikla J, Phan A, Raderer M, Sedlackova E . Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371(3):224-33. DOI: 10.1056/NEJMoa1316158. View

13.

Papaxoinis G, Lamarca A, Quinn A, Mansoor W, Nonaka D . Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations. Endocr Pathol. 2018; 29(3):259-268. PMC: 6097045. DOI: 10.1007/s12022-018-9530-y. View

14.

Ketai L, Mohammed T, Kirsch J, Kanne J, Chung J, Donnelly E . ACR appropriateness criteria® hemoptysis. J Thorac Imaging. 2014; 29(3):W19-22. DOI: 10.1097/RTI.0000000000000084. View

15.

Larici A, Franchi P, Occhipinti M, Contegiacomo A, Del Ciello A, Calandriello L . Diagnosis and management of hemoptysis. Diagn Interv Radiol. 2014; 20(4):299-309. PMC: 4463269. DOI: 10.5152/dir.2014.13426. View

16.

Olsen K, Manouchehr-Pour S, Donnelly E, Henry T, Berry M, Boiselle P . ACR Appropriateness Criteria® Hemoptysis. J Am Coll Radiol. 2020; 17(5S):S148-S159. DOI: 10.1016/j.jacr.2020.01.043. View

17.

Hofland J, Kaltsas G, de Herder W . Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2019; 41(2). PMC: 7080342. DOI: 10.1210/endrev/bnz004. View

18.

Danti G, Berti V, Abenavoli E, Briganti V, Linguanti F, Mungai F . Diagnostic imaging of typical lung carcinoids: relationship between MDCT, In-Octreoscan and F-FDG-PET imaging features with Ki-67 index. Radiol Med. 2020; 125(8):715-729. DOI: 10.1007/s11547-020-01172-4. View

19.

Santiago-Naranjo K, Ilaiwy A . Pulmonary carcinoid presenting with persistent pneumothorax. BMJ Case Rep. 2019; 12(11). PMC: 6855850. DOI: 10.1136/bcr-2019-231083. View

20.

Baghdadi A, Ghadimi M, Mirpour S, Hazhirkarzar B, Motaghi M, Pawlik T . Imaging neuroendocrine tumors: Characterizing the spectrum of radiographic findings. Surg Oncol. 2021; 37:101529. DOI: 10.1016/j.suronc.2021.101529. View